Fundamental dimension Equity attribute | LMLLFPeer $0.00340.00% Cap $456.3KP/E -0.9x QuantScore35/100 | BIOELeader $0.420.00% Cap $16.63MP/E 11.3x QuantScore77/100 | CNGGFPeer $0.0030.00% Cap $4.92MP/E 0.3x QuantScore48/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
38/100 |
73/100 |
77/100 |
Valuation Multiples, PEG & DCF upside | 33/100 | 77/100 | 67/100 |
Health Piotroski, Altman Z, leverage & liquidity | 20/100 | 60/100 | 24/100 |
Growth Revenue / earnings growth & margins | 50/100 | 100/100 | 25/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | -0.9x | 11.3x | 0.3x |
Forward P/E (next FY) | — | — | — |
EV / EBITDA (TTM) | -10.2x | 11.1x | -3.7x |
Price / Sales | — | 5.7x | 0.4x |
Price / Free Cash Flow | -7.5x | 15.5x | -2.0x |
PEG ratio | 0.01 | 0.01 | 0.00 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 2 / 9 | 6 / 9 | 4 / 9 |
Altman Z-Score | -78.47 (Distress) | 4.46 (Safe) | -4.99 (Distress) |
Total debt / equity | -0.95 | 0.67 | 0.59 |
Quick ratio | 0.0x | 0.4x | 0.3x |
Interest coverage | -0.6x | 706.6x | -2.2x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | — | +485.8% | -35.5% |
Net income growth YoY | +51.7% | +168.5% | +190.7% |
Gross margin (TTM) | 0.0% | 69.7% | -94.1% |
Operating margin (FY) | — | 47.4% | -140.3% |
FCF margin (FY) | — | 82.7% | -20.3% |
5. Trailing price performancePrice change over period |
1M return | -22.7% | +130.8% | +48.0% |
3M return | -34.0% | +55.6% | -12.9% |
6M return | -68.5% | -6.7% | -24.1% |
Year to date | -61.8% | +600.0% | -51.1% |
1Y return | -64.9% | +508.7% | -40.8% |
3Y return | -81.3% | -17.6% | -96.0% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $-0.0121 -454.5% premium | $-0.1693 -140.3% premium | $-0.0262 -984.7% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |